2002
DOI: 10.1016/s0168-1656(01)00425-4
|View full text |Cite
|
Sign up to set email alerts
|

Renaturation and purification of bone morphogenetic protein-2 produced as inclusion bodies in high-cell-density cultures of recombinant Escherichia coli

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

2
103
0
4

Year Published

2004
2004
2014
2014

Publication Types

Select...
9
1

Relationship

3
7

Authors

Journals

citations
Cited by 132 publications
(109 citation statements)
references
References 21 publications
2
103
0
4
Order By: Relevance
“…Recombinant human BMP4 and TGF-␤1 were purchased from R&D Systems (Wiesbaden, Germany), and recombinant human IL-1␤ was from RELIATech GmbH (Braunschweig, Germany). Recombinant human BMP2 from Escherichia coli was prepared as described (30). C3H10T 1 ⁄2-BMP2 cells were stably transfected with expression plasmids encoding wt TAK1, dominant-negative (dn) or constitutively active (ca) TAK1 in pMT7T3-f1 using DOSPER TM according to the manufacturer's protocol (Roche Applied Science) together with a selection plasmid conferring puromycin resistance (pBSpac⌬p, parental C3H10T 1 ⁄2 cells) or G418 resistance (pAG60, BMP2-expressing C3H10T 1 ⁄2 cells).…”
Section: Methodsmentioning
confidence: 99%
“…Recombinant human BMP4 and TGF-␤1 were purchased from R&D Systems (Wiesbaden, Germany), and recombinant human IL-1␤ was from RELIATech GmbH (Braunschweig, Germany). Recombinant human BMP2 from Escherichia coli was prepared as described (30). C3H10T 1 ⁄2-BMP2 cells were stably transfected with expression plasmids encoding wt TAK1, dominant-negative (dn) or constitutively active (ca) TAK1 in pMT7T3-f1 using DOSPER TM according to the manufacturer's protocol (Roche Applied Science) together with a selection plasmid conferring puromycin resistance (pBSpac⌬p, parental C3H10T 1 ⁄2 cells) or G418 resistance (pAG60, BMP2-expressing C3H10T 1 ⁄2 cells).…”
Section: Methodsmentioning
confidence: 99%
“…Recombinant BMPs have been obtained from mammalian cell cultures, but incomplete monomer processing and low yields are usual in these processes (6). Alternatively, the production of biologically active recombinant humans BMPs (rhBMPs) through in vitro refolding of Escherichia coli produced inclusion bodies has been reported (4,7). However, the refolding procedure is complicated and the overall yield is low.…”
Section: Introductionmentioning
confidence: 99%
“…After drying at 60°C for 30 min the implants were dipped again until the coverage consisted of three layers of silica. After calcination at 415°C for 4 h the samples were incubated with 10 % 3-aminopropyl trimethoxysilane (Sigma-Aldrich Chemie) in water for 2 min, dried and shaking in a solution of 250 µg ml -1 isolated recombinant human BMP-2 (see method in [5]) in 50 mM 2(Nmorpholino)ethanesulfonic acid buffer, pH 5 (SigmaAldrich Chemie) overnight at 4°C under gentle shaking, washed with 0.066% sodium dodecyl sulphate in 0.125 M sodium tetraborate buffer, pH10.0 (Sigma-Aldrich Chemie), transferred in phosphate-buffered saline (Gibco tm, Invitrogen Corporation, Paisley, UK) and implanted immediately.…”
Section: Methodsmentioning
confidence: 99%